Theragenics Corp (TGX) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2011

Exhibit 99.1

Theragenics^® Reports Revenue & Earnings for Fourth Quarter & Year-End 2011

Acquisition of Core Oncology Customer Base Expands Brachy Market Presence

BUFORD, Ga.--(BUSINESS WIRE)--February 23, 2012--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year-ended December 31, 2011.

Highlights

• Consolidated revenue
  • $19.9 million for the fourth quarter, down 4% from 2010
  • $82.7 million for the year, up 1% over 2010
• Segment revenue
  • Surgical products revenue down 5% in fourth quarter vs. 2010 and up 1% for year
  • Brachytherapy revenue up 1% in fourth quarter vs. 2010 and up 1% for year
• Earnings per share
  • $0.01 in the fourth quarter of 2011 vs. $0.01 in 2010
  • $0.09 for 2011 vs. $0.06 in 2010
• Adjusted EBITDA
  • $2.6 million in the fourth quarter of 2011 vs. $2.4 million in 2010
  • $13.5 million for 2011 vs. $11.6 million for 2010
• At December 31, 2011, cash, cash equivalents and marketable securities were $41.2 million, credit facility borrowings were $23.7 million, resulting in a net positive position of $17.5 million
• Acquisition of Core Oncology’s prostate brachytherapy customer base on February 17, 2012 is expected to substantially increase the Company’s share of the iodine-125 segment of the brachy market
  • $5 million to $6 million of incremental revenue expected in brachytherapy segment for remaining portion of calendar 2012
  • Expected to be accretive to earnings and generate positive operating cash flow in 2012
  • Total earn-out based purchase price is expected to be approximately $7.5 million to $10.5 million, which is based on anticipated revenue in the earn-out period of $10 million to $13 million from the acquired customers, in excess of a $2.5 million threshold amount.